Observes inclisiran use in adults with high cholesterol in Korea
Follows adults with high cholesterol who receive inclisiran in routine care.
Plain-language title generated from the registry record
Registry title: Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea)
Key facts
- Where
- Busan, Seoul, Taegu, and Yangsan, South KoreaSee the 4 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT06770543, who can take part
Where in South Korea
- BusanBusan, South KoreaTaking people
- SeoulSeoul, South KoreaTaking people
- TaeguTaegu, South KoreaTaking people
- YangsanYangsan, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT06770543
- Record updated
- 22 December 2025
- Original description
This non-interventional study is a mandatory regular Post Marketing Surveillance(rPMS) granted by the Korean health authorities, and is conducted to assess the effectiveness and safety of Leqvio® Pre-filled Syringe(inclisiran sodium) in routine clinical practice for the approved indications (primary hypercholesterolemia or mixed dyslipidemia).Read full original descriptionShow less
Regulatory Post-Marketing Surveillance (rPMS) Study for Leqvio® Pre-filled Syringe(Inclisiran Sodium)
This non-interventional study is a mandatory regular Post Marketing Surveillance(rPMS) granted by the Korean health authorities, and is conducted to assess the effectiveness and safety of Leqvio® Pre-filled Syringe(inclisiran sodium) in routine clinical practice for the approved indications (primary hypercholesterolemia or mixed dyslipidemia).
Inclusion: If a subject meets all of the following criteria, he/she can participate in this study:; Adult patients(18 years or older) who have hypercholesterolemia or mixed dyslipidemia and are prescribed Leqvio® Pre-filled Syringe(inclisiran sodium) according to domestically approved product information in real clinical practice; Patients who are unable to reach LDL-C target with maximum tolerated dose of statin, or patients with statin intolerance; Patients who provided consent to participate in the study(informed consent form).
Exclusion: Patients participating in clinical trials of other investigational drugs; A subjects who meets any of the following criteria cannot participate in this study:; Contraindications in accordance with domestic prescribing information; Patients who do not provide consent to participate in the study.